Resultados da pesquisa - Dirk Müller‐Wieland

Refinar resultados
  1. 1
    Obesity Associated with a Mutation in a Genetic Regulator of Adipocyte Differentiation

    Obesity Associated with a Mutation in a Genetic Regulator of Adipocyte Differentiation Por Michael Ristow, Dirk Müller‐Wieland, A. Pfeiffer, Wilhelm Krone, C. Ronald Kahn

    Publicado em 1998
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  2. 2
    Insulin-activated Erk-mitogen-activated Protein Kinases Phosphorylate Sterol Regulatory Element-binding Protein-2 at Serine Residues 432 and 455 in Vivo

    Insulin-activated Erk-mitogen-activated Protein Kinases Phosphorylate Sterol Regulatory Element-binding Protein-2 at Serine Residues 432 and 455 in Vivo Por Jörg Kotzka, Stefan Lehr, Gunther Roth, Haluk Avci, Birgit Knebel, Dirk Müller‐Wieland

    Publicado em 2004
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  3. 3
    SREBP-1 Mediates Activation of the Low Density Lipoprotein Receptor Promoter by Insulin and Insulin-like Growth Factor-I

    SREBP-1 Mediates Activation of the Low Density Lipoprotein Receptor Promoter by Insulin and Insulin-like Growth Factor-I Por Rüdiger Streicher, Jörg Kotzka, Dirk Müller‐Wieland, Gerhard Siemeister, Martina Munck, Haluk Avci, Wilhelm Krone

    Publicado em 1996
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  4. 4
    Five cases with central diabetes insipidus and hypogonadism as first presentation of neurosarcoidosis

    Five cases with central diabetes insipidus and hypogonadism as first presentation of neurosarcoidosis Por Catharina Bullmann, Michael Faust, Anne Lisbeth Hoffmann, Christina Heppner, F. Jockenhövel, Dirk Müller‐Wieland, W Krone

    Publicado em 2000
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  5. 5
    Definition, Classification and Diagnosis of Diabetes Mellitus

    Definition, Classification and Diagnosis of Diabetes Mellitus Por Astrid Petersmann, Dirk Müller‐Wieland, Ulrich Müller, Ruediger Landgraf, Matthias Nauck, Guido Freckmann, Lutz Heinemann, Erwin Schleicher

    Publicado em 2014
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  6. 6
    Liver-Specific Expression of Transcriptionally Active SREBP-1c Is Associated with Fatty Liver and Increased Visceral Fat Mass

    Liver-Specific Expression of Transcriptionally Active SREBP-1c Is Associated with Fatty Liver and Increased Visceral Fat Mass Por Birgit Knebel, Jutta Haas, Sonja Hartwig, Sylvia Jacob, Cornelia Köllmer, Ulrike Nitzgen, Dirk Müller‐Wieland, Jörg Kotzka

    Publicado em 2012
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  7. 7
    Sterol regulatory element binding proteins (SREBP)-1a and SREBP-2 are linked to the MAP-kinase cascade

    Sterol regulatory element binding proteins (SREBP)-1a and SREBP-2 are linked to the MAP-kinase cascade Por Jörg Kotzka, Dirk Müller‐Wieland, Gunther Roth, L. Kremer, Martina Munck, Sandra Schürmann, Birgit Knebel, Wilhelm Krone

    Publicado em 2000
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  8. 8
    Preventing Phosphorylation of Sterol Regulatory Element-Binding Protein 1a by MAP-Kinases Protects Mice from Fatty Liver and Visceral Obesity

    Preventing Phosphorylation of Sterol Regulatory Element-Binding Protein 1a by MAP-Kinases Protects Mice from Fatty Liver and Visceral Obesity Por Jörg Kotzka, Birgit Knebel, Jutta Haas, L. Kremer, Sylvia Jacob, Sonja Hartwig, Ulrike Nitzgen, Dirk Müller‐Wieland

    Publicado em 2012
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  9. 9
    Definition, Classification and Diagnosis of Diabetes Mellitus

    Definition, Classification and Diagnosis of Diabetes Mellitus Por Astrid Petersmann, Dirk Müller‐Wieland, Ulrich Müller, Rüdiger Landgraf, Matthias Nauck, Guido Freckmann, Lutz Heinemann, Erwin Schleicher

    Publicado em 2019
    Obter o texto integral Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  10. 10
    MAP Kinases Erk1/2 Phosphorylate Sterol Regulatory Element-binding Protein (SREBP)-1a at Serine 117 in Vitro

    MAP Kinases Erk1/2 Phosphorylate Sterol Regulatory Element-binding Protein (SREBP)-1a at Serine 117 in Vitro Por Gunther Roth, Jörg Kotzka, L. Kremer, Stefan Lehr, Christiane Lohaus, Helmut E. Meyer, Wilhelm Krone, Dirk Müller‐Wieland

    Publicado em 2000
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  11. 11
    Clinical course of COVID-19 patients needing supplemental oxygen outside the intensive care unit

    Clinical course of COVID-19 patients needing supplemental oxygen outside the intensive care unit Por Ayham Daher, Paul Balfanz, Maria Aetou, Bojan Hartmann, Dirk Müller‐Wieland, Tobias Müller, Nikolaus Marx, Michael Dreher, Christian Cornélissen

    Publicado em 2021
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  12. 12
    Follow up of patients with severe coronavirus disease 2019 (COVID-19): Pulmonary and extrapulmonary disease sequelae

    Follow up of patients with severe coronavirus disease 2019 (COVID-19): Pulmonary and extrapulmonary disease sequelae Por Ayham Daher, Paul Balfanz, Christian Cornélissen, Annegret Müller, Ingmar Bergs, Nikolaus Marx, Dirk Müller‐Wieland, Bojan Hartmann, Michael Dreher, Tobias Müller

    Publicado em 2020
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  13. 13
    <scp>L</scp>ow‐density lipoprotein cholesterol and non‐high‐density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large <scp>German–Austrian</scp> diabetes registry

    <scp>L</scp>ow‐density lipoprotein cholesterol and non‐high‐density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large <scp>German–Aus... Por Julia Brandts, Sascha R. Tittel, Peter Bramlage, Thomas Danne, Johanna Brix, Stefan Zimny, Christoph H. J. Heyer, Reinhard W. Holl, Dirk Müller‐Wieland

    Publicado em 2023
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  14. 14
    Efficacy and Safety of Ezetimibe Added to Atorvastatin Versus Atorvastatin Uptitration or Switching to Rosuvastatin in Patients With Primary Hypercholesterolemia

    Efficacy and Safety of Ezetimibe Added to Atorvastatin Versus Atorvastatin Uptitration or Switching to Rosuvastatin in Patients With Primary Hypercholesterolemia Por Harold Bays, Maurizio Averna, Claudio Majul, Dirk Müller‐Wieland, Annamaria De Pellegrin, Hilde Giezek, Raymond Lee, Robert S. Lowe, Philippe Brudi, Joseph Triscari, Michel Farnier

    Publicado em 2013
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  15. 15
    Therapy of Type 2 Diabetes

    Therapy of Type 2 Diabetes Por Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald Klein, Dirk Müller‐Wieland, Michael A. Nauck, Hans‐Martin Reuter, Erhard Siegel

    Publicado em 2019
    Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  16. 16
    Phosphorylation of sterol regulatory element-binding protein (SREBP)-1c by p38 kinases, ERK and JNK influences lipid metabolism and the secretome of human liver cell line HepG2

    Phosphorylation of sterol regulatory element-binding protein (SREBP)-1c by p38 kinases, ERK and JNK influences lipid metabolism and the secretome of human liver cell line HepG2 Por Birgit Knebel, Stefan Lehr, Sonja Hartwig, Jutta Haas, Gernot Kaber, Hans-Dieter Dicken, Franciscus Susanto, Lothar Bohne, Sylvia Jacob, Ulrike Nitzgen, Waltraud Paßlack, Dirk Müller‐Wieland, Jörg Kotzka

    Publicado em 2014
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  17. 17
    Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes

    Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes Por Dirk Müller‐Wieland, Monika Kellerer, Katarzyna Cypryk, Dasa Skripova, Katja Rohwedder, Eva Johnsson, Ricardo García‐Sánchez, Raisa Kurlyandskaya, C. David Sjöström, Stephan Jacob, Jochen Seufert, Nalina Dronamraju, Katalin Csomós

    Publicado em 2018
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  18. 18
    No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies

    No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies Por Helen M. Colhoun, Henry N. Ginsberg, Jennifer G. Robinson, Lawrence A. Leiter, Dirk Müller‐Wieland, Robert R. Henry, Bertrand Cariou, Marie T. Baccara‐Dinet, Robert Pordy, Laurence Merlet, Robert H. Eckel

    Publicado em 2016
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  19. 19
    Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies

    Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies Por Kausik K. Ray, Stefano Del Prato, Dirk Müller‐Wieland, Bertrand Cariou, Helen M. Colhoun, Francisco J. Tinahones, Catherine Domenger, Alexia Letierce, Jonas Mandel, Rita Samuel, Maja Bujas‐Bobanovic, Lawrence A. Leiter

    Publicado em 2019
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  20. 20
    Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The <scp>ODYSSEY DM‐INSULIN</scp> randomized trial

    Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The <scp>ODYSSEY DM‐INSULIN</scp> randomized trial Por Lawrence A. Leiter, Bertrand Cariou, Dirk Müller‐Wieland, Helen M. Colhoun, Stefano Del Prato, Francisco J. Tinahones, Kausik K. Ray, Maja Bujas‐Bobanovic, Catherine Domenger, Jonas Mandel, Rita Samuel, Robert R. Henry

    Publicado em 2017
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:

Ferramentas de pesquisa: